Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 17, 2026 07:25 ET | Source: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors

MELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
April 17, 2026 06:00 ET | Source: Immuron Limited

Immuron Double Digit 3Q Sales Growth

Sales Highlights (unaudited): Global Q3 sales AUD$1.5 million up 16% on prior comparative period (pcp)YTD Mar 2026 sales AUD$5.7 million up 7% on prior comparative period (pcp) Australia Q3 sales...
April 16, 2026 19:54 ET | Source: Paladin Energy Ltd

LHM Guidance Revision - Increase FY2026 Production Range

PERTH, Australia, April 16, 2026 (GLOBE NEWSWIRE) -- Paladin Energy Ltd (ASX:PDN, TSX:PDN, OTCQX:PALAF) (“Paladin” or the “Company”) provides an operations and guidance update for the Langer...
April 16, 2026 08:06 ET | Source: Amaero Ltd

Q3 FY2026 Investor Webinar

Q3 FY2026 Investor Webinar
April 16, 2026 07:25 ET | Source: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting

MELBOURNE, Australia and SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
April 16, 2026 07:00 ET | Source: Radiopharm Theranostics

Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases

Interim data to date showed 90% concordance with MRI (the primary endpoint) Clinical trial readout (Primary endpoint) expected in June 2026 Plans to advance RAD 101 into U.S. Phase 3 pivotal trial ...